GLP-1 Market
LLY $1137.82 ▲ +0.2% NVO $41.71 ▼ -1.9% PFE $27.46 ▼ -0.3% VKTX $29.52 ▼ -1.4% KLRA $12.70 ▼ -5.6% GPCR $35.50 ▼ -8.9% RHHBY $55.15 ▲ +0.4%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Pegloticase

Company
Amgen
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 17, 2026

Find a Clinical Trial Near Me

See recruiting studies for Pegloticase and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07388498

    A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled Gout

    Not yet reported Amgen 270 participants Est. completion 2028-06-18 71 sites Stand-alone
    Other conditions: Uncontrolled Gout
    View official trial listing →
  • Completed NCT NCT00080210

    A Study of Persons With Gout Who Do Not Respond to or Are Allergic to Conventional Therapy

    Not yet reported Savient Pharmaceuticals 40 participants Est. completion 2005-02 9 sites
    Other conditions: Gout
    View official trial listing →
  • Completed NCT NCT00111657

    Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout

    Not yet reported John Sundy 30 participants Est. completion 2009-07 1 site Stand-alone
    Other conditions: Gout
    View official trial listing →
  • Completed NCT NCT00325195

    Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout

    Not yet reported Savient Pharmaceuticals 225 participants Est. completion 2007-12 56 sites Stand-alone
    Other conditions: Gout
    View official trial listing →
  • Completed NCT NCT00675103

    Re-exposure Study of Pegloticase Intravenous (i.v.) in Symptomatic Gout Patients

    Not yet reported Savient Pharmaceuticals 7 participants Est. completion 2009-04 4 sites Stand-alone
    Other conditions: Chronic Gout Refractory to Conventional Therapy
    View official trial listing →
  • Completed NCT NCT01356498

    Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout

    Not yet reported Savient Pharmaceuticals 151 participants Est. completion 2010-01 22 sites Stand-alone
    Other conditions: Gout
    View official trial listing →
  • Completed NCT NCT01466166

    Observational Study of the Use of Pegloticase (KRYSTEXXA®) in Refractory Chronic Gout

    Horizon Pharma Rheumatology LLC 188 participants Est. completion 2017-06-30 67 sites
    Other conditions: Refractory Chronic Gout
    View official trial listing →
  • Completed NCT NCT01739660

    Study to Assess Pegloticase (KRYSTEXXA®) in Patients on Hemodialysis

    Not yet reported Savient Pharmaceuticals 12 participants Est. completion 2013-04 1 site Stand-alone
    Chronic kidney disease
    View official trial listing →
  • Completed NCT NCT02598596

    Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect

    Not yet reported Ampel BioSolutions, LLC 132 participants Est. completion 2020-04-27 11 sites Stand-alone
    Other conditions: Gout
    View official trial listing →
  • Completed NCT NCT03303989

    REduCing Immunogenicity to PegloticasE (RECIPE) Study

    Not yet reported University of Alabama at Birmingham 35 participants Est. completion 2021-03-31 1 site Stand-alone
    Other conditions: Gout Chronic
    View official trial listing →
  • Completed NCT NCT03635957

    Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout

    Not yet reported Amgen 14 participants Est. completion 2020-10-26 6 sites Stand-alone
    Other conditions: Gout
    View official trial listing →
  • Completed NCT NCT03899883

    Uric Acid Lowering Trial in Youth Onset T2D

    Not yet reported University of Colorado, Denver 11 participants Est. completion 2023-04-13 1 site Stand-alone
    Chronic kidney diseaseType 2 diabetes Other conditions: Hyperuricemia, Diabetes, Diabetic Nephropathies, Diabetes Complications
    View official trial listing →
  • Completed NCT NCT03905512

    A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Participants Refractory to Conventional Therapy

    Not yet reported Selecta Biosciences, Inc. 170 participants Est. completion 2020-08-05 43 sites
    Other conditions: Chronic Gout
    View official trial listing →
  • Completed NCT NCT03994731

    Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout

    Not yet reported Amgen 152 participants Est. completion 2022-04-11 60 sites Stand-alone
    Other conditions: Gout
    View official trial listing →
  • Completed NCT NCT04087720

    Study of Pegloticase in Participants With Uncontrolled Gout Who Have Had a Kidney Transplant

    Not yet reported Amgen 20 participants Est. completion 2021-09-07 8 sites Stand-alone
    Other conditions: Uncontrolled Gout, Kidney Transplant
    View official trial listing →
  • Completed NCT NCT04511702

    Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate

    Not yet reported Amgen 191 participants Est. completion 2024-03-25 39 sites Stand-alone
    Other conditions: Chronic Uncontrolled Gout, Gout, Uncontrolled Gout
    View official trial listing →
  • Completed NCT NCT04745910

    Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

    Not yet reported M.D. Anderson Cancer Center 10 participants Est. completion 2026-04-27 1 site Stand-alone
    Other conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Tumor Lysis Syndrome
    View official trial listing →
  • Completed NCT NCT04762498

    A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout (FORWARD OL)

    Not yet reported Amgen 54 participants Est. completion 2023-12-20 12 sites Stand-alone
    Other conditions: Uncontrolled Gout, Chronic Gout
    View official trial listing →
  • Completed NCT NCT04772313

    Pegloticase and Methotrexate Co-administered in Participants With Uncontrolled Gout Who Previously Failed Pegloticase Monotherapy

    Not yet reported Amgen 11 participants Est. completion 2023-04-24 15 sites Stand-alone
    Other conditions: Uncontrolled Gout
    View official trial listing →
  • Completed NCT NCT05302388

    A Study Exploring Efficacy of Pegloticase in Subjects With Asymptomatic Hyperuricemia

    Not yet reported Shanghai Institute Of Biological Products 45 participants Est. completion 2023-01-09 1 site
    Other conditions: Asymptomatic Hyperuricemia
    View official trial listing →
  • Completed NCT NCT06186219

    Recapturing Immune Tolerance to Pegloticase for the Management of Tophaceous Gout

    Not yet reported University of California, Los Angeles 2 participants Est. completion 2024-11-22 1 site Stand-alone
    Other conditions: Tophaceous Gout
    View official trial listing →
  • Completed NCT NCT06229145

    A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout

    Not yet reported Amgen 306 participants Est. completion 2026-03-26 74 sites Stand-alone
    Other conditions: Gout
    View official trial listing →
  • Active, not recruiting NCT NCT07116746

    Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients

    Not yet reported Arthrosi Therapeutics 15 participants Est. completion 2027-02 8 sites
    Other conditions: Gout, Gouty Arthritis, Hyperuricemia, Gout Chronic, Refractory Gout, Uncontrolled Gout, Tophaceous Gout
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Pegloticase, Krystexxa

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.